Α-Galactosidase from Escherichia coli (‚â•20 units/mg)

<strong>α-Galactosidase from Escherichia coli (≥20 units/mg)</strong>_x000D_ <strong>Catalog number:</strong> B2010737_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 60 Units_x000D_ <strong>Molecular Weight or Concentration:</strong> 80 kDa_x000D_ <strong>Supplied as:</strong> buffered aqueous solution_x000D_ <strong>Applications:</strong> multipurpose enzyme for various biochemical applications_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> a-galactosidase, a-gal_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Zarate YA, Hopkin RJ. Fabry's disease Lancet. 2008 Oct 18;372(9647):1427-35._x000D_ 2: Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JMFG, Artola M. Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions Biomolecules. 2021 Feb 12;11(2):271._x000D_ 3: Bhatia S, Singh A, Batra N, Singh J. Microbial production and biotechnological applications of α-galactosidase Int J Biol Macromol. 2020 May 1;150:1294-1313._x000D_ 4: Fabris E, Bulfoni M, Nencioni A, Nencioni E. Intra-Laboratory Validation of Alpha-Galactosidase Activity Measurement in Dietary Supplements Molecules. 2021 Mar 12;26(6):1566._x000D_ 5: Liu Y, Yang J, Wang K, Duan F, Lu L. Carrier-Free Immobilization of α-Galactosidase as Nano-Biocatalysts for Synthesizing Prebiotic α-Galacto-Oligosaccharides Molecules. 2021 Feb 25;26(5):1248._x000D_ 6: Stratilová B, Klaudiny J, Řehulka P, Stratilová E, Mészárosová C, Garajová S, Pavlatovská B, Řehulková H, Kozmon S, Šesták S, Firáková Z, Vadkertiová R. Characterization of a long-chain α-galactosidase from Papiliotrema flavescens World J Microbiol Biotechnol. 2018 Jan 4;34(2):19._x000D_ 7: Tarabuso AL. Fabry disease Skinmed. 2011 May-Jun;9(3):173-7._x000D_ 8: Dwyer B, Hu J, Madduri A, Lundberg D, Miller B, Gill J, Meiyappan M, Pan C, Miller T, Zhang B. Affinity purification of human alpha galactosidase utilizing a novel small molecule biomimetic of alpha-D-galactose Protein Expr Purif. 2021 Jan;177:105752._x000D_ 9: Lenders M, Brand E. Precision medicine in Fabry disease Nephrol Dial Transplant. 2021 Jun 22;36(Suppl 2):14-23._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33015742">10: Yang L, Shi G, Tao Y, Lai C, Li X, Zhou M, Yong Q. The Increase of Incomplete Degradation Products of Galactomannan Production by Synergetic Hydrolysis of β-Mannanase and α-Galactosidase Appl Biochem Biotechnol. 2021 Feb;193(2):405-416. </a>_x000D_ _x000D_ <strong>Products Related to α-Galactosidase from Escherichia coli (≥20 units/mg)</strong><a href="https://moleculardepot.com/product-category/Enzymes/">: Enzymes</a>